Pranoprofen

Drug Profile

Pranoprofen

Alternative Names: Difen Oculum; difen oculum; Niflan; Niflan Ophthalmic Solution; Oftalar; Pranopulin Ophthalmic Solution; Pranox; SJH 1012; Y 8004

Latest Information Update: 05 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Developer Alcon Cusi; Allergan; Mitsubishi Tanabe Pharma Corporation; Senju Pharmaceutical; Takeda
  • Class Benzopyrans; Nonsteroidal anti-inflammatories; Propionic acids
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Fever; Inflammation; Ocular inflammation; Pain

Most Recent Events

  • 01 Oct 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku to form Mitsubishi Tanabe Pharma Corporation
  • 06 Apr 2000 Yoshitomi is now called Welfide Corporation
  • 31 Dec 1999 Launched for Ocular inflammation in Czech Republic (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top